Literature DB >> 26072686

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

Alexander M Menzies1,2, Iwei Yeh3, Thomas Botton3, Boris C Bastian3, Richard A Scolyer1,2,4, Georgina V Long1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26072686      PMCID： PMC4539279          DOI： 10.1111/pcmr.12388

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  10 in total

1.  A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Authors:  Junfeng Xia; Peilin Jia; Katherine E Hutchinson; Kimberly B Dahlman; Douglas Johnson; Jeffrey Sosman; William Pao; Zhongming Zhao
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

2.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

3.  Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Authors:  Thierry Passeron; Jean-Philippe Lacour; Maryline Allegra; Coralie Ségalen; Anne Deville; Antoine Thyss; Damien Giacchero; Jean-Paul Ortonne; Corine Bertolotto; Robert Ballotti; Philippe Bahadoran
Journal:  Exp Dermatol       Date:  2011-12       Impact factor: 3.960

4.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

5.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

6.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Authors:  Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2013-08-19       Impact factor: 4.693

7.  BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Authors:  Katherine E Hutchinson; Doron Lipson; Philip J Stephens; Geoff Otto; Brian D Lehmann; Pamela L Lyle; Cindy L Vnencak-Jones; Jeffrey S Ross; Jennifer A Pietenpol; Jeffrey A Sosman; Igor Puzanov; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2013-12-15       Impact factor: 12.531

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

9.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

10.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

Authors:  Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2014-01-14       Impact factor: 17.388
  10 in total
  30 in total

1.  Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

Authors:  Huat C Lim; Meagan Montesion; Thomas Botton; Eric A Collisson; Sarah E Umetsu; Spencer C Behr; John D Gordan; Phil J Stephens; Robin K Kelley
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

3.  BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Authors:  Douglas B Johnson; Merrida A Childress; Zachary R Chalmers; Garrett M Frampton; Siraj M Ali; Samuel M Rubinstein; David Fabrizio; Jeffrey S Ross; Sohail Balasubramanian; Vincent A Miller; Philip J Stephens; Jeffrey A Sosman; Christine M Lovly
Journal:  Pigment Cell Melanoma Res       Date:  2017-12-16       Impact factor: 4.693

Review 4.  A review of kinase fusions in melanocytic tumors.

Authors:  Sara C Shalin
Journal:  Lab Invest       Date:  2016-11-28       Impact factor: 5.662

5.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.

Authors:  Yu-Chien Kao; Valentina Ranucci; Lei Zhang; Yun-Shao Sung; Edward A Athanasian; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

Review 6.  Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors.

Authors:  Emilie Perron; Daniel Pissaloux; Angela Neub; Daniel Hohl; Marie Dominique Tartar; Laurent Mortier; Laurent Alberti; Arnaud de la Fouchardiere
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

Review 7.  Melanoma: What do all the mutations mean?

Authors:  Elizabeth J Davis; Douglas B Johnson; Jeffrey A Sosman; Sunandana Chandra
Journal:  Cancer       Date:  2018-04-17       Impact factor: 6.860

8.  Kinase gene fusions in defined subsets of melanoma.

Authors:  Jacqueline Turner; Kasey Couts; Jamie Sheren; Siriwimon Saichaemchan; Witthawat Ariyawutyakorn; Izabela Avolio; Ethan Cabral; Magdelena Glogowska; Carol Amato; Steven Robinson; Jennifer Hintzsche; Allison Applegate; Eric Seelenfreund; Rita Gonzalez; Keith Wells; Stacey Bagby; John Tentler; Aik-Choon Tan; Joshua Wisell; Marileila Varella-Garcia; William Robinson
Journal:  Pigment Cell Melanoma Res       Date:  2017-01       Impact factor: 4.693

Review 9.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

10.  Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Authors:  Lise Boussemart; Annie Nelson; Michael Wong; Jeffrey S Ross; Jeffrey Sosman; Janice Mehnert; Gregory Daniels; Kari Kendra; Siraj Mahamed Ali; Vincent A Miller; Alexa B Schrock
Journal:  Oncologist       Date:  2019-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.